January 20, 2026

​

Exciva GmbH today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW. 

Download Press Release >>>

​

February 12, 2025

​

Fiona Hattey joined the Exciva team as Head of Clinical Operations. She has over thirty years of experience in operationalizing clinical trials.

​

November 4, 2024

​

Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US FDA

​

April 1, 2024

Dr Hans Moebius, co-founder of Exciva, re-joined the team as a Chief Medical Officer bringing with him over thirty years of leadership in Neurology and Psychiatry drug development and translational medicine

​

June 1, 2023

Francisco Orellana, a seasoned professional who has worked in the biotech sector for over twenty years, joined Exciva as Chief Financial Officer

​

October 25, 2022

The US PTO granted a patent to Exciva for its invention of innovative composition of matter with various therapeutic uses in neuropsychiatry

​​

October 11, 2022

Exciva successfully completed Phase I study of its proprietary EXV-802 combination of dextromethorphan and a 5-HT2A/2C receptor inverse agonist

​

October 26, 2021

Exciva raises €9 million in Series A round led by Andera Partners (full press release)​​

​